Literature DB >> 6282138

Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation.

T J Berndt, J D Pfeifer, F G Knox, S A Kempson, T P Dousa.   

Abstract

Results of previous studies suggest a potentially important role for nicotinamide adenine dinucleotide (NAD) in the cellular regulation of phosphate transport by the renal proximal tubules. The present clearance studies were performed to evaluate whether intraperitoneal administration of nicotinamide, a precursor of NAD and inhibitor of NAD catabolism, would not only increase phosphate excretion but also restore the phosphaturic response to parathyroid hormone (PTH) in rats fed a low phosphate diet. Rats fed a low phosphate diet were resistant to the phosphaturic effect of PTH, calcitonin, and dibutyryl cAMP (DBcAMP) in spite of the fact that all three agents elicited an increase in the urinary excretion of cAMP. Administration of nicotinamide to rats fed a low phosphate diet increased renal cortical NAD levels, increased phosphate excretion, partially restored the phosphaturic effect of PTH and DBcAMP, and completely restored the phosphaturic response to calcitonin. We conclude that nicotinamide restores the phosphaturic effect of PTH and calcitonin in rats fed a low phosphate diet by acting at a cellular step subsequent to cAMP generation to inhibit tubular reabsorption of phosphate.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282138     DOI: 10.1152/ajprenal.1982.242.5.F447

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  The inhibition of parathyroid-hormone actions on gluconeogenesis and phosphate transport by 3-mercaptopicolinate in rabbit renal proximal tubules.

Authors:  N Yanagawa; O D Jo
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

Review 2.  Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Authors:  Tamara Isakova; Joachim H Ix; Stuart M Sprague; Kalani L Raphael; Linda Fried; Jennifer J Gassman; Dominic Raj; Alfred K Cheung; John W Kusek; Michael F Flessner; Myles Wolf; Geoffrey A Block
Journal:  J Am Soc Nephrol       Date:  2015-05-12       Impact factor: 10.121

3.  A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.

Authors:  Steven C Cheng; Daniel O Young; Yihung Huang; James A Delmez; Daniel W Coyne
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

Review 4.  Nicotinamide and phosphate homeostasis in chronic kidney disease.

Authors:  Charles Ginsberg; Joachim H Ix
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

5.  Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis.

Authors:  J Vasantha; P Soundararajan; N Vanitharani; G Kannan; P Thennarasu; G Neenu; C Umamaheswara Reddy
Journal:  Indian J Nephrol       Date:  2011-10

Review 6.  Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

Authors:  Aurélie Lenglet; Sophie Liabeuf; Pauline Guffroy; Albert Fournier; Michel Brazier; Ziad A Massy
Journal:  Drugs R D       Date:  2013-09

Review 7.  Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.

Authors:  Denis Fouque; Marc Vervloet; Markus Ketteler
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

8.  Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease.

Authors:  N S Zahed; N Zamanifar; H Nikbakht
Journal:  Indian J Nephrol       Date:  2016 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.